Valproate-Induced Hyperammonemic Encephalopathy Successfully Treated With Levocarnitine in an Elderly Patient Without Liver Dysfunction

An 87-year-old male with a history of seizure disorder on long-term prophylaxis with valproate and concomitant levetiracetam presented with impaired consciousness and anorexia. The evaluation revealed a markedly elevated blood ammonia level of 518 μmol/L and decreased serum carnitine levels, leading to a diagnosis of valproate-induced hyperammonemic encephalopathy in the absence of liver dysfunction. Discontinuation of valproate, continuation of levetiracetam, and initiation of levocarnitine supplementation and branched-chain amino acid infusion resulted in a durable resolution of symptoms. This case underscores the importance of promptly considering valproate-induced hyperammonemic encephalopathy due to carnitine depletion in patients on long-term valproate therapy who develop acute encephalopathy and initiating levocarnitine treatment for effective management.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2024-12-30
DOI
https://doi.org/10.7759/cureus.76603
Primary Topic
Pharmacological Effects and Toxicity Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Valproate-Induced Hyperammonemic Encephalopathy Successfully Treated With Levocarnitine in an Elderly Patient Without Liver Dysfunction

Hisafumi Kihara, Hisaharu Shikata, Masahiko Kaneko
Cureus
Pharmacological Effects and Toxicity Studies
article

Valproate-Induced Hyperammonemic Encephalopathy Successfully Treated With Levocarnitine in an Elderly Patient Without Liver Dysfunction

Hisafumi Kihara, Hisaharu Shikata, Masahiko Kaneko
article en

Abstract

An 87-year-old male with a history of seizure disorder on long-term prophylaxis with valproate and concomitant levetiracetam presented with impaired consciousness and anorexia. The evaluation revealed a markedly elevated blood ammonia level of 518 μmol/L and decreased serum carnitine levels, leading to a diagnosis of valproate-induced hyperammonemic encephalopathy in the absence of liver dysfunction. Discontinuation of valproate, continuation of levetiracetam, and initiation of levocarnitine supplementation and branched-chain amino acid infusion resulted in a durable resolution of symptoms. This case underscores the importance of promptly considering valproate-induced hyperammonemic encephalopathy due to carnitine depletion in patients on long-term valproate therapy who develop acute encephalopathy and initiating levocarnitine treatment for effective management.

CureusVol. 16(12)
Uwajima City Hospital (JP)
Openalex Percentile: Top 62%
Pharmacological Effects and Toxicity Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Valproate-Induced Hyperammonemic Encephalopathy Successfully Treated With Levocarnitine in an Elderly Patient Without Liver Dysfunction — Hisafumi Kihara, Hisaharu Shikata, et al. · Cureus (2024) | TGRS Research Map | TGRS